Drug Trial Radar · NCT06631430
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 30, 2024
Primary completion
Jun 12, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.
Conditions
- Healthy
Interventions
BI 3810477Drug
BI 3810477 formulation A
BI 3810477Drug
BI 3810477 formulation B
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: Up to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Science Services - Clinical Research
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.